AbbVie receives the option to license worldwide rights to CUG252 from Cugene, a clinical-stage and potential best-in-class Treg-selective IL-2 mutein, building on AbbVie's commitment to developing novel therapies in immunology
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
The new hospital is expected to open by March'24
The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone
For the first time in India – fast, precise and efficient calibration of multi-channel micropipettes
The licences will allow manufacturers from around the world to work with MPP and C-TAP to make these technologies accessible to people living in low- and middle-income countries
Capabilities include the latest in sterile lyophilization and liquid filling technology to support global pharmaceutical supply chain, keeping pace with industry trends
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
NextSWAB is currently optimized for nasal sample collection with validation for other sample types ongoing
ArisGlobal acquires Boehringer Ingelheim’s Benefit-Risk Analytic System (BRASS), a software solution designed to support causal analysis of drug safety data in a highly regulated environment
Subscribe To Our Newsletter & Stay Updated
